Liraglutide in Children and Adolescents with Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 381; no. 7; pp. 637 - 646
• Main Authors: Tamborlane, William V, Barrientos-Pérez, Margarita, Fainberg, Udi, Frimer-Larsen, Helle, Hafez, Mona, Hale, Paula M, Jalaludin, Muhammad Y, Kovarenko, Margarita, Libman, Ingrid, Lynch, Jane L, Rao, Paturi, Shehadeh, Naim, Turan, Serap, Weghuber, Daniel, Barrett, Timothy
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 15.08.2019
• Subjects: Adolescent; Adolescents; Age; Antidiabetics; Blood Glucose - analysis; Child; Children; Children & youth; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Drug Therapy, Combination; Fasting; Female; Gastrointestinal Diseases - chemically induced; Glycated Hemoglobin - analysis; Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - therapeutic use; Insulin resistance; Laboratory testing; Liraglutide - administration & dosage; Liraglutide - adverse effects; Liraglutide - therapeutic use; Male; Medicin och hälsovetenskap; Metformin; Metformin - adverse effects; Metformin - therapeutic use; Patient safety; Pediatrics; Peptides; Statistical analysis; Teenagers; United Kingdom > UK
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1903822

This trial assessed the efficacy and safety of liraglutide as compared with placebo, added to metformin (with or without basal insulin treatment), in children and adolescents with type 2 diabetes. The addition of liraglutide was efficacious and relatively safe in improving glycemic control over 52 weeks.